CHAIRMAN’S STATEMENT

Cytomyx PLC is going through significant changes. In November, I was named by the board to take charge of the company. Although this company had significant changes, I believe there are interesting business opportunities moving forward.

With the complete of human genome project, the field of individualized medicine is increasing becoming a clinical reality. The centerpiece of individualized medicine is the discovery and validation of clinically important biomarkers which can improve significantly the diagnosis and treatment of various diseases.

Cytomyx LLC, the remaining core business unit of Cytomyx Plc, is uniquely positioned as a potential leader in the field of biomarker discovery and validation. The company has collected over 200,000 clinically important human tissue samples over the years and has over 100 customers who rely on Cytomyx’s tissue repository and clinical data for biomarker discovery and validation.

We are planning to change our core business of a pure biorepository into a human tissue based biomarker discovery and validation company. For this reason, we are positioning the company as “Cytomyx-The Biomarker Company”. This is a very exciting and dynamic market. We believe that there will be significant value to be created in this field.

Wei-Wu He, Ph.D.

Chairman and CEO

January 2007